Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin lymphoma (NHL) is a broad term covering more than 60 distinct malignancies that arise from lymphocytes — the white blood cells of the immune system. B-cell lymphomas account for approximately 85% of NHL; T-cell and NK-cell lymphomas make up the remaining 15%. NHL is characterized by the clonal proliferation of lymphocytes that have undergone malignant transformation at various stages of their development.

Hodgkin lymphoma (HL) is a distinct entity defined by the presence of Reed-Sternberg cells — large abnormal B-cells with a characteristic 'owl-eye' appearance on biopsy. HL is generally more predictably curable with standard chemotherapy (ABVD or BEACOPP) and is highly sensitive to checkpoint immunotherapy. NHL, by contrast, is biologically diverse — ranging from indolent diseases managed for years to aggressive lymphomas requiring urgent intensive treatment. The two categories have different epidemiology, clinical behavior, and treatment approaches.

NHL diagnosis requires a tissue biopsy — fine needle aspiration (FNA) alone is not sufficient. An excisional lymph node biopsy (removing an intact lymph node) or a core needle biopsy with multiple passes provides the tissue needed for comprehensive evaluation. The biopsy specimen undergoes: morphologic assessment by a hematopathologist; immunohistochemistry (IHC) with a comprehensive antibody panel; FISH for key chromosomal rearrangements (MYC, BCL2, BCL6, CCND1, ALK); and, in many centers, an NGS panel for mutational profiling.

Beyond the biopsy, the workup includes PET-CT staging, bone marrow biopsy, blood tests (LDH, beta-2 microglobulin, full blood count, liver and kidney function), EBV serology, HIV testing, and hepatitis B/C serology — with lumbar puncture for CNS assessment in high-risk aggressive NHL. This comprehensive approach takes time but is essential — initiating treatment before the subtype is fully characterized risks using the wrong protocol.

Aggressive NHL — including DLBCL, mantle cell lymphoma, and Burkitt lymphoma — grows rapidly and, if untreated, can be life-threatening within weeks to months. It requires urgent initiation of intensive treatment. The good news is that many aggressive NHL subtypes are potentially curable: approximately 60% of DLBCL patients are cured with first-line R-CHOP or pola-R-CHP.

Indolent NHL — including follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma — grows slowly, often over years. While generally not curable with standard therapy, it can be managed effectively for many years. A critical principle in indolent NHL is that immediate treatment is not always necessary — for asymptomatic patients with low tumor burden, watchful waiting ('watch and wait') is appropriate and delays treatment toxicity without harming outcomes. The treatment approach in indolent NHL is calibrated to the patient's symptoms and disease burden, not the stage alone.

Double-hit lymphoma — formally called High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements (HGBL) — is a distinct and aggressive category of large B-cell lymphoma defined by concurrent chromosomal rearrangements of both the MYC gene and the BCL2 gene. These concurrent rearrangements simultaneously activate a powerful growth driver (MYC) and block apoptosis (BCL2), producing a uniquely aggressive tumor biology.

Double-hit lymphoma is clinically important because it does not respond as well to standard R-CHOP as conventional DLBCL, and patients treated with R-CHOP alone have significantly worse outcomes. Intensified regimens — most commonly DA-R-EPOCH — are used instead. FISH testing for MYC and BCL2 (and BCL6 for 'triple-hit') is mandatory in all newly diagnosed DLBCL. If this testing was not done at your diagnosis, or results are missing, this should be urgently addressed before treatment planning is finalized.

CAR-T (chimeric antigen receptor T-cell) therapy is a personalized cellular immunotherapy in which the patient's own T-cells are collected, genetically engineered in a laboratory to express a receptor that recognizes the CD19 protein on lymphoma cells, and then infused back into the patient after lymphodepleting chemotherapy. The engineered T-cells multiply and attack CD19-expressing lymphoma cells. Three CAR-T products are approved for NHL: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) — each with somewhat different risk profiles and approved indications.

CAR-T is currently approved for relapsed or refractory DLBCL and follicular lymphoma after two or more prior lines of therapy, and — based on recent trial data — for second-line DLBCL that is primary refractory or early relapsed (within 12 months of first-line). Eligibility requires CD19-positive disease, adequate organ function, and absence of active CNS lymphoma. Manufacturing requires approximately 3–4 weeks; patients may receive bridging therapy during this period. CAR-T requires specialist center infrastructure and is not universally available — CancerFax can assist in identifying centers and supporting international coordination.

Bispecific CD20xCD3 antibodies — including epcoritamab and glofitamab (for DLBCL) and mosunetuzumab (for follicular lymphoma) — simultaneously bind CD20 on lymphoma cells and CD3 on T-cells, physically bringing a T-cell into close proximity with the lymphoma cell and activating the T-cell to kill it. Unlike CAR-T, bispecific antibodies are 'off-the-shelf' ready-made drugs that do not require personalized manufacturing — they can be started within days rather than weeks.

Bispecific antibodies produce meaningful response rates in relapsed/refractory DLBCL and FL. Their primary toxicity is cytokine release syndrome (CRS) — managed with step-up dosing and hospitalization for early cycles. They represent an important alternative for patients who cannot wait for CAR-T manufacturing, who have had prior CAR-T, or who are treated at centers without CAR-T programs. Ongoing trials are evaluating bispecific antibodies in earlier lines and in combination with standard chemoimmunotherapy.

Not necessarily. For patients with asymptomatic, low-tumor-burden follicular lymphoma — defined by criteria such as no B symptoms, no rapidly enlarging nodes, no organ compromise, no significant bone marrow failure, and no large tumor masses — active surveillance ('watch and wait') is an appropriate and evidence-based initial strategy. Multiple clinical trials have confirmed that immediate treatment of asymptomatic low-tumor-burden FL does not improve survival compared to deferred treatment when symptoms or disease progression develops.

Watch and wait means regular monitoring (typically every 3 months initially, then less frequently if stable) with clinical assessment and periodic imaging. Treatment is initiated when defined criteria are met: symptoms develop, disease bulk increases significantly, organ function is threatened, or hematologic parameters worsen. When treatment is initiated, rituximab-based chemoimmunotherapy (typically bendamustine + rituximab) followed by rituximab maintenance is the current standard for advanced-stage symptomatic FL. For relapsed EZH2-mutant FL, tazemetostat provides a targeted molecular option.

Yes — NHL is one of the most active areas of hematologic oncology research globally, and China has particular importance in this space, especially for cellular therapies. China has been a global pioneer in CAR-T cell therapy development and has multiple active trials that are not yet available in other countries: FasT CAR-T programs with very short manufacturing timelines (as little as 24 hours), dual-targeting CAR-T products (CD19+CD22 or CD19+CD20) designed to prevent antigen escape, and 'armored' CAR-T constructs with improved T-cell persistence and effector function. Multiple phase II and III trials are running at centers such as Beijing's CAMS, Peking University Cancer Hospital, and Ruijin Hospital in Shanghai.

Beyond China, active international trial areas include first-line bispecific antibody combinations, MRD-guided therapy de-escalation in FL, T-cell lymphoma-specific programs (IDH2 inhibitors in AITL, ALK inhibitors in ALCL), and allogeneic CAR-T. CancerFax can assist in reviewing your NHL subtype and treatment history against open trial criteria and facilitating contact with enrolling centers, including in China.

Yes. CancerFax supports NHL patients and families through the complete treatment navigation process. We start with a detailed review of your biopsy report, IHC panel, FISH results, NGS profiling, PET-CT staging, and treatment history to establish your exact lymphoma subtype, molecular risk classification, and disease status — because in NHL, these details determine everything about which treatment is appropriate.

Based on this review, we identify which standard and advanced treatment options apply — from R-CHOP or pola-R-CHP for newly diagnosed DLBCL, to rituximab maintenance and watch-and-wait for indolent FL, to BTK inhibitors for MCL or WM, tazemetostat for EZH2-mutant FL, and CAR-T cell therapy or bispecific antibodies for relapsed disease. We coordinate second opinion consultations with specialist lymphoma hematologists and facilitate international treatment navigation for patients seeking access to CAR-T programs, clinical trials, or specialist centers in India, China, or globally. Send your medical reports to get started.